TMBR.Q Stock Overview
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Timber Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0002 |
52 Week High | US$3.36 |
52 Week Low | US$0.0001 |
Beta | -1.48 |
1 Month Change | -83.33% |
3 Month Change | -83.33% |
1 Year Change | -99.99% |
3 Year Change | -100.00% |
5 Year Change | n/a |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
TMBR.Q | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 100.0% | 1.2% | 0.4% |
1Y | -100.0% | 25.8% | 28.8% |
Return vs Industry: TMBR.Q underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.
Return vs Market: TMBR.Q underperformed the US Market which returned 28.8% over the past year.
Price Volatility
TMBR.Q volatility | |
---|---|
TMBR.Q Average Weekly Movement | 147.9% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TMBR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: TMBR.Q's weekly volatility has decreased from 644% to 148% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 9 | John Koconis | https://www.timberpharma.com |
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company’s lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea.
Timber Pharmaceuticals, Inc. Fundamentals Summary
TMBR.Q fundamental statistics | |
---|---|
Market cap | US$308.00 |
Earnings (TTM) | -US$14.93m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs TMBR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TMBR.Q income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$8.73m |
Gross Profit | -US$8.73m |
Other Expenses | US$6.21m |
Earnings | -US$14.93m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -4.84 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did TMBR.Q perform over the long term?
See historical performance and comparison